Ibrutinib as a treatment of hematologic ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
Auteur(s) :
Daniel, Adrien [Auteur]
Université de Lille
Ghez, David [Auteur]
Radiothérapie Moléculaire et Innovation Thérapeutique [RaMo-IT]
Ravaiau, Camille [Auteur]
Cavalieri, Doriane [Auteur]
CHU Clermont-Ferrand
Tournilhac, Olivier [Auteur]
CHU Estaing [Clermont-Ferrand]
Herbaux, Charles [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Roriz, Mélanie [Auteur]
Wemeau, Mathieu [Auteur]
Centre Hospitalier de Roubaix
Guillet, Stéphanie [Auteur]
Bossard, Jean-Baptiste [Auteur]
Centre Hospitalier de Lens
Demarquette, Hélène [Auteur]
Kaphan, Eleonore [Auteur]
Université Grenoble Alpes - UFR Médecine [UGA UFRM]
Regny, Caroline [Auteur]
Lachenal, Florence [Auteur]
Centre Hopitalier Pierre Oudot [Bourgoin-Jallieu]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Michel, Marc [Auteur]
Hôpital Henri Mondor
Godeau, Bertrand [Auteur]
Hôpital Henri Mondor
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Université de Lille
Ghez, David [Auteur]
Radiothérapie Moléculaire et Innovation Thérapeutique [RaMo-IT]
Ravaiau, Camille [Auteur]
Cavalieri, Doriane [Auteur]
CHU Clermont-Ferrand
Tournilhac, Olivier [Auteur]
CHU Estaing [Clermont-Ferrand]
Herbaux, Charles [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Roriz, Mélanie [Auteur]
Wemeau, Mathieu [Auteur]
Centre Hospitalier de Roubaix
Guillet, Stéphanie [Auteur]
Bossard, Jean-Baptiste [Auteur]
Centre Hospitalier de Lens
Demarquette, Hélène [Auteur]
Kaphan, Eleonore [Auteur]
Université Grenoble Alpes - UFR Médecine [UGA UFRM]
Regny, Caroline [Auteur]
Lachenal, Florence [Auteur]
Centre Hopitalier Pierre Oudot [Bourgoin-Jallieu]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Michel, Marc [Auteur]
Hôpital Henri Mondor
Godeau, Bertrand [Auteur]
Hôpital Henri Mondor
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Titre de la revue :
European Journal of Haematology
Nom court de la revue :
Eur J Haematol
Numéro :
109
Pagination :
719-727
Date de publication :
2022-09-09
ISSN :
1600-0609
Mot(s)-clé(s) en anglais :
B-cell lymphoma
hematologic immune disorders
ibrutinib
hematologic immune disorders
ibrutinib
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved ...
Lire la suite >Background Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B-cell lymphomas. Results We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B-cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune-mediated bleeding disorders) were included. Twenty-five patients were identified. Median age at ibrutinib introduction was 69 years (range 44–84) and median number of previous treatment lines before ibrutinib was 2 (1–7). Twenty-two patients (88%) were on concomitant stable treatment at inclusion. Within a median exposure of 8 months (2–35), overall response rate to ibrutinib on immune manifestations was 76% (95% CI, 54.9–90.6); complete response rate 44%. Fourteen patients (63%) were able to be weaned from concomitant treatments. Fourteen patients (56%) presented treatment-related adverse events, mostly Grade 1 or 2. Conclusions Ibrutinib in this setting provides good efficacy and safety profile. Clinical trials are needed to define subgroups of patients who will benefit from this strategy and establish its place in the therapeutic arsenal.Lire moins >
Lire la suite >Background Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B-cell lymphomas. Results We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B-cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune-mediated bleeding disorders) were included. Twenty-five patients were identified. Median age at ibrutinib introduction was 69 years (range 44–84) and median number of previous treatment lines before ibrutinib was 2 (1–7). Twenty-two patients (88%) were on concomitant stable treatment at inclusion. Within a median exposure of 8 months (2–35), overall response rate to ibrutinib on immune manifestations was 76% (95% CI, 54.9–90.6); complete response rate 44%. Fourteen patients (63%) were able to be weaned from concomitant treatments. Fourteen patients (56%) presented treatment-related adverse events, mostly Grade 1 or 2. Conclusions Ibrutinib in this setting provides good efficacy and safety profile. Clinical trials are needed to define subgroups of patients who will benefit from this strategy and establish its place in the therapeutic arsenal.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2024-01-12T00:43:01Z
2024-03-28T12:26:53Z
2024-03-28T12:26:53Z
Fichiers
- European J of Haematology - 2022 - Daniel - Ibrutinib as a treatment of hematologic autoimmune disorders in patients with.pdf
- Non spécifié
- Accès libre
- Accéder au document